Mumbai-based drug company Cipla said that its U.S. subsidiary InvaGen Pharmaceuticals Inc formalized a two-stage agreement to acquire specialty pharmaceutical company Avenue Therapeutics Inc for $215 million. New York-based Avenue is focused on the development and commercialization of intravenous (IV) Tramadol. The transaction will be subject to Avenue stockholders’ and...